Jiangsu Hengrui Pharmaceutical, China’s largest drug company by market capitalisation, has signed a global collaboration and licensing agreement with US pharmaceutical giant Bristol Myers Squibb (BMS) worth up to US$15.2 billion.Hengrui’s Hong Kong-traded shares climbed 5.3 per cent to HK$69.55 on Tuesday, while its Shenzhen stock rose 4.84 per cent to 56.11 yuan.The deal adds credibility to China’s growing reputation for innovative drug development. Industry players, however, said the country still had some way to go before it gained a “genuine voice” in the global pharmaceutical industry.
SRCSouth China Morning Post
LANGEN
LEANCenter-Right
WORDS87
ENT6
TUE · 2026-05-12 · 10:00 GMTBRIEF NSR-2026-0512-75608
NSR-2026-0512-75608News Report·EN·Economic Impact
China’s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS
Chinese pharmaceutical giant Jiangsu Hengrui Pharmaceutical has entered into a global collaboration and licensing agreement with US-based Bristol Myers Squibb (BMS). The deal is valued at up to US$15.2 billion.
Julie ZhangSouth China Morning PostFiled 2026-05-12 · 10:00 GMTLean · Center-RightRead · 1 min
South China Morning PostFIG 01
Reading time
1min
Word count
87words
Sources cited
0cited
Entities identified
6entities
Quality score
100%
§ 01
Briefing Summary
AI-generatedNEWSAR · AI
Chinese pharmaceutical giant Jiangsu Hengrui Pharmaceutical has entered into a global collaboration and licensing agreement with US-based Bristol Myers Squibb (BMS). The deal is valued at up to US$15.2 billion. This significant partnership, announced recently, involves Hengrui's innovative drug development capabilities. The agreement saw Hengrui's stock prices increase on both the Hong Kong and Shenzhen exchanges. This collaboration is seen as a step forward for China's pharmaceutical industry, enhancing its global standing in drug innovation, though industry observers note further development is needed for a more prominent global voice.
Confidence 0.85Claims 5Entities 6
§ 02
Article analysis
Model · rule-basedFraming
Economic Impact
Technology
Tone
Measured
AI-assessed
CalmNeutralAlarmist
Factuality
0.80 / 1.00
Factual
LowHigh
Sources cited
0
No named sources
FewMany
§ 03
Key claims
5 extracted01
Hengrui’s Hong Kong-traded shares climbed 5.3 per cent to HK$69.55 on Tuesday.
statistic
Confidence
1.00
02
Jiangsu Hengrui Pharmaceutical signed a global collaboration and licensing agreement with Bristol Myers Squibb (BMS) worth up to US$15.2 billion.
factual
Confidence
1.00
03
Hengrui’s Shenzhen stock rose 4.84 per cent to 56.11 yuan.
statistic
Confidence
1.00
04
Industry players said China still had some way to go before it gained a “genuine voice” in the global pharmaceutical industry.
quoteIndustry players
Confidence
0.90
05
The deal adds credibility to China’s growing reputation for innovative drug development.
factual
Confidence
0.80
§ 04
Full report
1 min read · 87 words§ 05
Entities
6 identifiedKey playerOppositionContextPositiveNeutralNegative
Organizations2
§ 06
Keywords & salience
10 termspharmaceutical giant
1.00
global collaboration
0.90
licensing agreement
0.90
drug development
0.80
hengrui
0.70
bristol myers squibb
0.70
us
0.60
china
0.60
deal
0.50
market capitalisation
0.40
§ 07
Topic connections
Interactive graph Network visualization showing 2 related topics
View Full Graph Person Organization Location Event|Click node to navigate|Edge numbers = shared articles